Du är här


Cytokinetics, Inc.: Cytokinetics Announces Additional Data From BENEFIT-ALS to be Presented at the Joint Congress of European Neurology

South San Francisco, CA, May 27, 2014

Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that additional data
linded E
valuation of N
euromuscular E
ffects and F
unctional I
mprovement with T

S) will be presented during an oral presentation scheduled at the Joint
Congress of European Neurology to be held May 31 - June 3, 2014 at the
International Congress Center in Istanbul, Turkey.

Oral Presentation at the Joint Congress of European Neurology

Title: New Data from BENEFIT-ALS: Blinded Evaluation of Neuromuscular Effects
and Functional Improvement withTirasemtiv
in ALS

Presenter: Jeremy M. Shefner, M.D., Ph.D
Date: Sunday, June 1, 2014
Session Time: 4:45 PM - 6:15 PM
Session: Oral Session 2.2 "Motor Neurone Diseases"
Room: Hamidiye


, a novel skeletal muscle activator, is the lead drug candidate from
Cytokinetics' skeletal muscle contractility program. Tirasemtiv
selectively activates the fast skeletal muscle troponin complex by increasing
its sensitivity to calcium and, in preclinical studies, demonstrated
increases in skeletal muscle force in response to neuronal input and delays
in the onset and reductions in the degree of muscle fatigue. BENEFIT-ALS was
a Phase IIb, multinational, double-blind, randomized, placebo-controlled
clinical trial designed to evaluate the safety, tolerability and potential
efficacy oftirasemtiv
in patients with amyotrophic lateral sclerosis (ALS). BENEFIT-ALS did not
achieve its primary efficacy endpoint, the mean change from baseline in the
ALS Functional Rating Scale in its revised form (ALSFRS-R). Treatment
resulted in a statistically significant and potentially clinically meaningful
reduction in the decline of Slow Vital Capacity (SVC), a measure of the
strength of the skeletal muscles responsible for breathing that has been
shown to be an important predictor of disease progression and survival in
prior trials of patients with ALS. The analyses of other pre-specified
secondary efficacy endpoints produced mixed results. Results from
BENEFIT-ALS were presented at the 66th Annual Meeting of the American Academy
of Neurology on April 29, 2014. Cytokinetics expects to continue to analyze
the data from BENEFIT-ALS to inform the potential further development
in patients living with ALS.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program,omecamtiv mecarbil
, is in Phase II clinical development for the potential treatment of heart
failure. Amgen Inc. holds an exclusive license worldwide to develop and
commercializeomecamtiv mecarbil
and related compounds, subject to Cytokinetics' specified development and
commercialization participation rights. Cytokinetics is independently
, a fast skeletal muscle activator, as a potential treatment for diseases and
medical conditions associated with neuromuscular dysfunction.Tirasemtiv
is the subject of a Phase II clinical trials program and has been granted
orphan drug designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the European
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis
(ALS). Cytokinetics is collaborating with Astellas Pharma Inc. to develop
CK-2127107, a skeletal muscle activator structurally distinct fromtirasemtiv
, for non-neuromuscular indications. All of these drug candidates have arisen
from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell.
Additional information about Cytokinetics can be obtained

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' research and development
activities, including the potential significance and utility of the results
from preclinical studies and clinical trials of tirasemtiv; planned further
analyses of the results from BENEFIT-ALS and the potential outcomes of such
analyses; potential further development of tirasemtiv; and the properties and
potential benefits of tirasemtiv and Cytokinetics' other drug candidates.
Such statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, the results of BENEFIT-ALS may not support
further clinical development of tirasemtiv; further clinical development of
tirasemtiv in ALS patients, if supported by the BENEFIT-ALS data, will
require significant additional funding, and Cytokinetics may be unable to
obtain such additional funding on acceptable terms, if at all; potential
difficulties or delays in the development, testing, regulatory approvals for
trial commencement, progression or product sale or manufacturing, or
production of Cytokinetics' drug candidates that could slow or prevent
clinical development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be indicative
of future clinical trials results, patient enrollment for or conduct of
clinical trials may be difficult or delayed, Cytokinetics' drug candidates
may have adverse side effects or inadequate therapeutic efficacy, the U.S.
Food and Drug Administration or foreign regulatory agencies may delay or
limit Cytokinetics' or its partners' ability to conduct clinical trials, and
Cytokinetics may be unable to obtain or maintain patent or trade secret
protection for its intellectual property; Amgen's and Astellas' decisions
with respect to the design, initiation, conduct, timing and continuation of
development activities for omecamtiv mecarbil and CK-2127107, respectively;
Cytokinetics may incur unanticipated research and development and other costs
or be unable to obtain additional financing necessary to conduct development
of its products; Cytokinetics may be unable to enter into future
collaboration agreements for its drug candidates and programs on acceptable
terms, if at all; standards of care may change, rendering Cytokinetics' drug
candidates obsolete; competitive products or alternative therapies may be
developed by others for the treatment of indications Cytokinetics' drug
candidates and potential drug candidates may target; and risks and
uncertainties relating to the timing and receipt of payments from its
partners, including milestones and royalties on future potential product
sales under Cytokinetics' collaboration agreements with such partners. For
further information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the Securities
and Exchange Commission.

Joanna L. Goldstein
Manager, Investor Relations&Corporate Communications
(650) 624-3000


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cytokinetics, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.